Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35

Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

0.00

Guggenheim analyst Michael Schmidt maintains Tango Therapeutics (NASDAQ: TNGX) with a Buy and raises the price target from $32 to $35.